tumor necrosis factor receptor 2

Target id: 1871

Nomenclature: tumor necrosis factor receptor 2

Abbreviated Name: TNFR2

Systematic Nomenclature: TNFRSF1B

Family: Tumour necrosis factor (TNF) receptor family

Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	461	1p36.22	TNFRSF1B	TNF receptor superfamily member 1B
Mouse	1	474	4 78.17 cM	Tnfrsf1b	tumor necrosis factor receptor superfamily, member 1b
Rat	1	474	5q36	Tnfrsf1b	TNF receptor superfamily member 1B

Previous and Unofficial Names
CD120b \| TNF-R2 \| p75 TNFR \| TNFalpha-R2 \| TNF-R75 \| TNFRII \| tumor necrosis factor receptor superfamily, member 1B \| tumor necrosis factor receptor superfamily

Database Links
Alphafold	P20333 (Hs), P25119 (Mm), Q80WY6 (Rn)
ChEMBL Target	CHEMBL1250356 (Hs)
Ensembl Gene	ENSG00000028137 (Hs), ENSMUSG00000028599 (Mm), ENSRNOG00000016575 (Rn)
Entrez Gene	7133 (Hs), 21938 (Mm), 156767 (Rn)
Human Protein Atlas	ENSG00000028137 (Hs)
KEGG Gene	hsa:7133 (Hs), mmu:21938 (Mm), rno:156767 (Rn)
OMIM	191191 (Hs)
Pharos	P20333 (Hs)
UniProtKB	P20333 (Hs), P25119 (Mm), Q80WY6 (Rn)
Wikipedia	TNFRSF1B (Hs)

Natural/Endogenous Ligands
lymphotoxin-α {Sp: Human}
tumour necrosis factor membrane form {Sp: Human}

Adaptor proteins (Human)
TRAF1, TRAF2, TRAF5

Adaptor proteins (Human)

TRAF1, TRAF2, TRAF5

Other Binding Ligands

Key to terms and symbols

Click column headers to sort

Ligand	Sp.	Action	Value	Parameter
lymphotoxin-α {Sp: Human}	Hs	-	-	-
⤷
tumour necrosis factor membrane form {Sp: Human}	Hs	-	-	-
⤷

Immunopharmacology Comments
TNFR2 is a receptor for lymphotoxin-α, and the membrane form of tumour necrosis factor (TNF). It plays a variety of important roles in immune system development and regulation [4-5], mediating immune suppression and tissue regeneration. It achieves immune suppression by influencing activation and proliferation of TNFR2-expressing T_reg cells [2]. TNFR2 on T_reg cells in the tumour microenvironment and on tumour cells is considered to be a therapeutically tractable target for novel immuno-oncology agents [7]. TNFR2 antagonistic antibodies [3] have the potential to reduce T_reg and cancer cell activation and/or proliferation [1,6], and concomittantly promote proliferation of T_eff cells, further contributing to immune system-mediated destruction of tumour cells.

Immunopharmacology Comments

TNFR2 is a receptor for lymphotoxin-α, and the membrane form of tumour necrosis factor (TNF). It plays a variety of important roles in immune system development and regulation [4-5], mediating immune suppression and tissue regeneration. It achieves immune suppression by influencing activation and proliferation of TNFR2-expressing T_reg cells [2]. TNFR2 on T_reg cells in the tumour microenvironment and on tumour cells is considered to be a therapeutically tractable target for novel immuno-oncology agents [7]. TNFR2 antagonistic antibodies [3] have the potential to reduce T_reg and cancer cell activation and/or proliferation [1,6], and concomittantly promote proliferation of T_eff cells, further contributing to immune system-mediated destruction of tumour cells.

Immuno Process Associations

Immuno Process:

Inflammation

Immuno Process:

Cytokine production & signalling

Immuno Process:

Immuno Process:

Immuno Process:

Immuno Process:

References

Show »« Hide

1. Chen X, Oppenheim JJ. (2017) Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal, 10 (462). [PMID:28096506]

2. Chen X, Wu X, Zhou Q, Howard OM, Netea MG, Oppenheim JJ. (2013) TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol, 190 (3): 1076-84. [PMID:23277487]

3. Fischer R, Marsal J, Guttà C, Eisler SA, Peters N, Bethea JR, Pfizenmaier K, Kontermann RE. (2017) Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep, 7 (1): 6607. [PMID:28747780]

4. Gubernatorova EO, Tumanov AV. (2016) Tumor Necrosis Factor and Lymphotoxin in Regulation of Intestinal Inflammation. Biochemistry Mosc, 81 (11): 1309-1325. [PMID:27914457]

5. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper MD, Browning JL, Sedgwick JD, Cyster JG. (1999) Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med, 189 (2): 403-12. [PMID:9892622]

6. Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D et al.. (2017) Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal, 10 (462). [PMID:28096513]

7. Vanamee ÉS, Faustman DL. (2017) TNFR2: A Novel Target for Cancer Immunotherapy. Trends Mol Med, 23 (11): 1037-1046. [PMID:29032004]